321 related articles for article (PubMed ID: 22314606)
1. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges.
Coppola A; Tagliaferri A; Di Capua M; Franchini M
Semin Thromb Hemost; 2012 Feb; 38(1):79-94. PubMed ID: 22314606
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis in people with haemophilia.
Coppola A; Franchini M; Tagliaferri A
Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
[TBL] [Abstract][Full Text] [Related]
3. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis for severe hemophilia: experience from Europe and the United States.
van den Berg HM; Fischer K
Semin Thromb Hemost; 2003 Feb; 29(1):49-54. PubMed ID: 12640565
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
6. Prevention of arthropathy in haemophilia: prophylaxis.
Santagostino E; Mancuso ME
Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
[TBL] [Abstract][Full Text] [Related]
7. A healthy hemophilic patient without arthropathy: from concept to clinical reality.
Berntorp E; Michiels JJ
Semin Thromb Hemost; 2003 Feb; 29(1):5-10. PubMed ID: 12640559
[TBL] [Abstract][Full Text] [Related]
8. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
Mancuso ME; Graca L; Auerswald G; Santagostino E
Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
[TBL] [Abstract][Full Text] [Related]
9. Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.
Giordano P; Lassandro G; Valente M; Molinari AC; Ieranò P; Coppola A
Pediatr Hematol Oncol; 2014 Nov; 31(8):687-702. PubMed ID: 25006797
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic therapy in haemophilia.
Ljung R
Blood Rev; 2009 Nov; 23(6):267-74. PubMed ID: 19775786
[TBL] [Abstract][Full Text] [Related]
11. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
[TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy.
Van den Berg HM; Dunn A; Fischer K; Blanchette VS
Haemophilia; 2006 Jul; 12 Suppl 3():159-68. PubMed ID: 16684012
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hemophilia: a review of current advances and ongoing issues.
Coppola A; Di Capua M; Di Minno MN; Di Palo M; Marrone E; Ieranò P; Arturo C; Tufano A; Cerbone AM
J Blood Med; 2010; 1():183-95. PubMed ID: 22282697
[TBL] [Abstract][Full Text] [Related]
14. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
15. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
17. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
18. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands.
van Dijk K; Fischer K; van der Bom JG; Scheibel E; Ingerslev J; van den Berg HM
Br J Haematol; 2005 Jul; 130(1):107-12. PubMed ID: 15982352
[TBL] [Abstract][Full Text] [Related]
19. Central venous access devices in patients with hemophilia.
Valentino LA; Kapoor M
Expert Rev Med Devices; 2005 Nov; 2(6):699-711. PubMed ID: 16293097
[TBL] [Abstract][Full Text] [Related]
20. Results of secondary prophylaxis in children with severe hemophilia.
Manco-Johnson MJ; Nuss R; Geraghty S; Funk S; Kilcoyne R
Am J Hematol; 1994 Oct; 47(2):113-7. PubMed ID: 8092125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
